The Gamaleya National Research Center for Epidemiology and Microbiology is working on a drug to combat antibiotic resistance, and Phase Three trials are now underway, according to the center’s director, Alexander Gintsburg.
“The next preparation that will be in high demand for the whole world’s population is a medication that addresses the issue of antibiotic resistance. Antibiotic resistance does not grow to such a drug, which has a broad spectrum of action. We’re almost to the end of Phase Three of this drug’s trials right now,” Ginsburg told Russia-24 television.
The creator emphasized the preparation’s revolutionary essence, arguing that its mechanism of action varies from antibiotics in several respects.
“Despite this, it’s applicable to the same issues as antibiotics do. However, rather than destroying a bacterium by shutting off its main vital functions, the major vital factors of bacterial pathogenicity may be turned off without affecting the bacterium’s proliferation. It disarms it first, and then our body’s immune system destroys the already disarmed bacterium using the most traditional methods, such as phagocytosis (when cells fully digest each other) and the same unique antibodies formed against this bacterium that are no longer harmful in the presence of this drug,” the developer added.
